Strategic Licensing Milestone

In April 2025, Redox Therapeutics entered into an exclusive license agreement with The Curators of the University of Missouri, acting through Missouri University of Science and Technology (Missouri S&T), for patented polymer nanoparticle technology developed for the removal of endotoxin from fluids.